---
title: "RPRX.US (RPRX.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/RPRX.US/news.md"
symbol: "RPRX.US"
name: "RPRX.US"
parent: "https://longbridge.com/en/quote/RPRX.US.md"
datetime: "2026-05-20T16:55:08.374Z"
locales:
  - [en](https://longbridge.com/en/quote/RPRX.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/RPRX.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/RPRX.US/news.md)
---

# RPRX.US (RPRX.US) — Related News

### [Commerzbank Aktiengesellschaft FI Invests $982,000 in Royalty Pharma PLC $RPRX](https://longbridge.com/en/news/286665997.md)
*2026-05-17T08:13:30.000Z*
> Commerzbank Aktiengesellschaft FI invested approximately $982,000 in Royalty Pharma PLC by purchasing 25,417 shares duri

### [Royalty Pharma PLC (NASDAQ:RPRX) Given Consensus Rating of "Buy" by Analysts](https://longbridge.com/en/news/286645485.md)
*2026-05-16T12:34:11.000Z*
> Royalty Pharma PLC (NASDAQ:RPRX) has received a consensus 'Buy' rating from seven brokerages. Analysts have set an avera

### [The Company is in Advanced Negotiations to Join Quest for Health and Expand into Strasbourg](https://longbridge.com/en/news/286224284.md)
*2026-05-13T08:35:21.000Z*
> Vidac Pharma Holding PLC is in advanced negotiations to join Quest for Health, a leading European life sciences accelera

### [Bank of America Securities Keeps Their Buy Rating on Royalty Pharma (RPRX)](https://longbridge.com/en/news/285577132.md)
*2026-05-07T13:59:17.000Z*
> Bank of America Securities has maintained a Buy rating on Royalty Pharma (RPRX) with a price target of $62.00. Analyst J

### [Royalty Pharma (RPRX) Gets a Buy from TD Cowen](https://longbridge.com/en/news/285498617.md)
*2026-05-07T06:36:08.000Z*
> TD Cowen analyst Michael Nedelcovych has maintained a Buy rating on Royalty Pharma (RPRX) with a price target of $50.00.

### [Royalty Pharma Q1 Profit, Revenue Increase; Raises Full-year Portfolio Receipts Outlook](https://longbridge.com/en/news/285494299.md)
*2026-05-07T06:20:45.000Z*
> Royalty Pharma plc (RPRX) reported a rise in Q1 earnings, with net income before tax increasing to $468 million from $43

### [Royalty Pharma Reports Q1 2026 Results: Full Earnings Call Transcript](https://longbridge.com/en/news/285392455.md)
*2026-05-06T13:56:40.000Z*
> Royalty Pharma (NASDAQ:RPRX) reported strong Q1 2026 results, with a 10% growth in portfolio receipts and 13% in royalty

### [Royalty Pharma plc 1Q 2026: Revenue $630.58M, EPS $0.67— 10-Q Summary](https://longbridge.com/en/news/285385401.md)
*2026-05-06T13:11:01.000Z*
> Royalty Pharma plc reported Q1 2026 results with revenue of $630.58M, net income of $294.69M, and diluted EPS of $0.67, 

### [Royalty Pharma PLC - CL | 8-K: FY2026 Q1 Revenue: USD 631 M](https://longbridge.com/en/news/285368181.md)
*2026-05-06T11:34:05.000Z*